How to Help Your Patients Save Money on Pyridostigmine: A Provider's Guide to Savings Programs

Pyridostigmine is generally inexpensive in its generic immediate-release (IR) form, but the extended-release (ER) formulation can cost hundreds to over $800 per month without insurance — a significant barrier for patients who rely on it for myasthenia gravis control. When the generic ER is in short supply and patients are forced toward brand-name Mestinon Timespan, cost becomes a crisis.

As a provider, you play a key role in connecting patients with cost-saving resources. This guide covers the most effective savings strategies — from patient assistance programs to formulation choices to prior authorization.

Understanding the Cost Landscape

As of 2026, pricing varies widely by formulation:

Generic Pyridostigmine IR 60 mg (90 tablets): Retail cash price $75–$125; with GoodRx or SingleCare: $25–$35. Often covered on Tier 1–2 with most insurance plans.

Generic Pyridostigmine ER 180 mg (30 tablets): Retail cash price $490–$750 when available; with GoodRx: $80–$150. May require prior authorization on some insurance plans.

Brand-name Mestinon Timespan 180 mg (30 tablets): $800+ list price; generally requires prior authorization; discount cards rarely make a significant dent. PAP is the key access route for uninsured patients.

Savings Strategy 1: Recommend Prescription Discount Cards

For patients on the IR formulation, prescription discount cards offer the fastest and easiest savings. Cards like GoodRx, SingleCare, and Optum Perks are free, require no enrollment, and work at most pharmacies. As of 2026:

GoodRx: as low as $25.51 for 90 tablets of Pyridostigmine IR 60 mg — 66% off retail

SingleCare: approximately $26.54 for 90 tablets of Pyridostigmine IR 60 mg

GoodRx for Pyridostigmine ER: as low as $79.82 for 30 tablets — 84% off retail when available

Discount cards are used instead of insurance. Advise patients to ask their pharmacist to run both their insurance copay and the discount card price to determine which is lower before completing the transaction.

Savings Strategy 2: Bausch Health Patient Assistance Program

For uninsured or underinsured patients who need brand-name Mestinon Timespan (particularly when generic ER is unavailable), Bausch Health's Patient Assistance Program (PAP) is the most impactful resource available:

Program: Bausch Health Patient Assistance Program

Website: bauschhealthpap.com

Benefit: Brand-name Mestinon Timespan (and other brand-name Mestinon products) at no cost for eligible patients

Eligibility: Uninsured or underinsured patients meeting income criteria (typically tied to federal poverty level guidelines)

Provider role: Your office will need to complete the prescriber portion of the application and provide a prescription. Consider designating a staff member to handle PAP applications for your MG patient population.

Savings Strategy 3: Prior Authorization for ER Formulation During Shortage

When the generic ER is unavailable and you need to prescribe brand-name Mestinon Timespan, many insurers will require prior authorization. A well-constructed PA request has a high probability of approval in this context. Key documentation to include:

Confirmed diagnosis of myasthenia gravis with relevant diagnostic workup (antibody panel, EMG results)

Medical necessity for the ER formulation specifically (e.g., GI intolerance of IR, nocturnal symptoms, compliance issues with frequent dosing)

Documentation that the generic ER is on back order and unavailable at local pharmacies (include specific pharmacy names and dates if possible)

Clinical rationale for why switching to IR tablets is not appropriate for this specific patient (if applicable)

39,049+ patients found their medications in stock

39K+

Find Pyridostigmine In Stock Today →

Savings Strategy 4: Prescribe the Formulation With the Best Access Profile

For newly diagnosed patients or those whose disease can be managed with either formulation, consider whether the IR 60 mg tablets are a clinically appropriate choice. The dramatic cost difference ($25–$35 vs. $80–$150+ with discount cards) can significantly reduce financial burden. Some clinical considerations:

Patients with mild-to-moderate MG who are well-controlled may do equally well on IR tablets with an appropriate dosing schedule

Patients with significant nocturnal symptoms or who cannot tolerate frequent dosing have stronger medical justification for the ER formulation

Patients with severe GI side effects on IR tablets may require the ER formulation for tolerability

Savings Strategy 5: 90-Day Supply and Mail-Order

For stable patients on the IR formulation, prescribing a 90-day supply reduces the per-unit cost compared to monthly fills. Most insurance plans and mail-order pharmacies offer better rates for 90-day fills. When appropriate, write 90-day prescriptions with 2–3 refills. Mail-order pharmacies (Express Scripts, CVS Caremark, Amazon Pharmacy) also tend to have more consistent supply for generics.

Skip the calls, skip the stress.

Find Pyridostigmine In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Medicare Part D Considerations

For Medicare patients, as of 2026, Medicare Part D has a $2,100 annual out-of-pocket cap on covered medications. This is particularly relevant for patients who take multiple expensive medications — once they reach the cap, covered medications are free for the rest of the year. The Medicare Extra Help/Low-Income Subsidy (LIS) program can also dramatically reduce costs for eligible patients with low income.

Helping Patients Find Pyridostigmine in Stock

Cost is only one barrier — availability is another. Directing patients to medfinder.com/providers can help them find their specific formulation in stock at local pharmacies without hours of calls. This is particularly valuable for MG patients who already have limited energy and mobility.

Share our patient-facing savings guide — How to Save Money on Pyridostigmine in 2026 — with patients directly.